Featured content in this Issue:
- Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure”
- An “Unauthorized Disclosure”
- “Canadian Reorganization”
- “Cost Containment Initiatives”
- Algernon Pharmaceuticals Makes DMT Stroke Research Program Its Lead Asset
- atai Pivots to IV Formulation of Ibogaine
- Seaport Therapeutics Launches with $100m Series A, Pipeline Includes ‘Prodrug of a Non-Hallucinogenic Neuroplastogen’
- Otsuka and Click Score FDA Clearance for Rejoyn, First Prescription Digital Therapeutic for A Mental Health Condition.
- Do Psilocybin Trial Participants Believe in the ‘Inner Healer’?
- LSD Microdosing Improves Sleep, According to New Publication
- “Petition for the FDA to Convene an Open Advisory Committee Meeting to Hear Concerns on MDMA-Assisted Therapy”
Companies, organisations and drug candidates mentioned in this Bulletin: Numinus Wellness; The Dales Report; Algernon Pharmaceuticals; AP-188; Seyltx; atai Life Sciences; IBX-210; DMX-1002; Seaport Therapeutics; Karuna; SPT-348; Otsuka; Click Therapeutics; Rejoyn; Lykos Therapeutics.
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
